Neuromodulatory therapies in female pelvic medicine and reconstructive surgery: biological agents.
In recent years, important improvements in the management of patients with neurogenic or non-neurogenic detrusor overactivity and urge incontinence have been brought about by the introduction of vanilloids and botulinum toxins in urology. In this review we introduce the new therapeutic options, provides basic information, and summarize the results experienced so far.
Schulte-Baukloh
Heinrich
H
Department of Urology, St. Hedwig Hospital, Teaching Hospital of University Hospital Charité, Berlin, Germany. hschultebaukloh@hotmail.com
Knispel
Helmut H
HH
D001905:Botulinum Toxins / Q000627:therapeutic use*; D002211:Capsaicin / Q000627:therapeutic use*; D004224:Diterpenes / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D009498:Neurotoxins / Q000627:therapeutic use*; D017773:Pelvic Floor; D016896:Treatment Outcome; D001743:Urinary Bladder / Q000187:drug effects; D001750:Urinary Bladder, Neurogenic / Q000188:drug therapy; D014549:Urinary Incontinence / Q000188:drug therapy*
D004224:Diterpenes; D009498:Neurotoxins; C024353:resiniferatoxin; D001905:Botulinum Toxins; D002211:Capsaicin